Blueprint Medicines Corporation focuses on Ayvakit, BLU-808, and Elenestinib with strong potential in mast cell disorders.

The following is a summary of “Prevalence of Mast Cell Activation Disorders and Hereditary Alpha Tryptasemia Amongst POTS and ...

According to the American College of Allergy Asthma and Immunology, nearly one in three U.S. adults report having a seasonal ...

Many patients report that infections, particularly viral illnesses or tick-borne diseases, preceded their symptom onset. Research increasingly supports the concept of “mast cell priming ...

The CDC advises that if you see mold in your home, no matter what type it is, "you need to clean up the mold and fix the moisture problem." ...

Jasper Therapeutics, Inc.’s JSPR share price has surged by 7.55%, which has investors questioning if this is right time to sell.

Blueprint Medicines' strong pipeline and Ayvakit growth make it promising. Read why BPMC stock is rated "Hold" due to high valuation and future drug risks.

Readers reply to an essay on overdiagnosis in medicine.

Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This Year Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for ...

A modern Western diet, high in processed foods and low in whole plant-based foods, can contribute to chronic inflammation but ...

Learn more about whether Alvotech or Blueprint Medicines Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The traditional African diet is rich in vegetables, fruit, beans, wholegrains, and fermented foods, points out internist ...